Atara Biotherapeutics presents preclinical ATA3219 data at ISCT 2024

The company stated: “Atara Biotherapeutics announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases. Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells. The data will be presented in a poster session at the International Society for Cell & Gene Therapy 2024 Annual Meeting taking place May 29 to June 1, 2024, in Vancouver, Canada. ATA3219 consists of allogeneic CD19-directed CAR EBV T cells that have been optimized to offer a potential best-in-class profile and off-the-shelf availability. It incorporates multiple clinically validated technologies including a modified CD3 signaling domain that sustains potent effector function while modulating activation and inflammation; a less differentiated phenotype for robust expansion and persistence; and no modification of the endogenous T-cell receptor as a key T-cell survival signal.” “Following exciting early clinical data with autologous CD19 CAR T in autoimmune patients, we believe there is an opportunity to further improve long-term efficacy, reduce toxicity and simplify treatment through our optimized allogeneic CD19 CAR T cells,” said Cokey Nguyen, Chief Scientific & Technical Officer at Atara. “We are pleased to share promising preclinical data that shows ATA3219 mediates robust B-cell depletion against SLE and multiple sclerosis patient derived immune cells. Importantly, ATA3219 is an off-the-shelf option that shows a favorable inflammatory profile that may lead to less toxicity and improved tolerability in the clinic. We look forward to continued evaluation of ATA3219 for the treatment of non-Hodgkin’s lymphoma, lupus nephritis, and in a recently announced cohort expansion for severe SLE without lymphodepletion.”